Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,187 | 250 | 99.1% |
| Education | $48.00 | 2 | 0.9% |
| Unspecified | $0 | 4 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $991.41 | 76 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $926.44 | 8 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $420.67 | 27 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $322.92 | 4 | $0 (2024) |
| Janssen Biotech, Inc. | $247.59 | 21 | $0 (2023) |
| Intercept Pharmaceuticals, Inc. | $245.88 | 6 | $0 (2024) |
| Braintree Laboratories, Inc. | $214.53 | 9 | $0 (2023) |
| PFIZER INC. | $166.94 | 7 | $0 (2023) |
| Merck Sharp & Dohme LLC | $160.88 | 9 | $0 (2023) |
| Allergan, Inc. | $131.11 | 9 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $389.05 | 19 | ABBVIE INC. ($173.68) |
| 2023 | $926.33 | 39 | AbbVie Inc. ($206.71) |
| 2022 | $794.04 | 39 | ABBVIE INC. ($207.36) |
| 2021 | $586.19 | 11 | Janssen Scientific Affairs, LLC ($230.49) |
| 2020 | $91.37 | 5 | Takeda Pharmaceuticals U.S.A., Inc. ($46.19) |
| 2019 | $450.21 | 12 | Janssen Scientific Affairs, LLC ($229.80) |
| 2018 | $1,250 | 78 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($248.10) |
| 2017 | $748.34 | 53 | AbbVie, Inc. ($145.44) |
All Payment Transactions
256 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: IMMUNOLOGY | ||||||
| 09/24/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $19.48 | General |
| Category: IMMUNOLOGY | ||||||
| 08/05/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $21.58 | General |
| Category: IMMUNOLOGY | ||||||
| 08/05/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $6.30 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: IMMUNOLOGY | ||||||
| 06/11/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $105.39 | General |
| 05/23/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $5.90 | General |
| Category: ENDOCRINOLOGY | ||||||
| 05/01/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: IMMUNOLOGY | ||||||
| 04/09/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $12.31 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/09/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $3.41 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/02/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $38.32 | General |
| Category: Neuroscience | ||||||
| 04/02/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $38.32 | General |
| Category: Neuroscience | ||||||
| 03/26/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $5.82 | General |
| Category: IMMUNOLOGY | ||||||
| 03/20/2024 | Ipsen Biopharmaceuticals, Inc | Bylvay (Drug) | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: Gastroenterology | ||||||
| 02/27/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $15.22 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 02/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: IMMUNOLOGY | ||||||
| 01/31/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: IMMUNOLOGY | ||||||
| 2024 | GastroGPO, LLC | — | — | — | $0.00 | Ownership |
| 12/05/2023 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $19.18 | General |
| 11/07/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $21.22 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2023 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/31/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $22.96 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/10/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 702 | 718 | $463,669 | $85,899 |
| 2022 | 16 | 632 | 652 | $419,618 | $74,850 |
| 2021 | 11 | 553 | 566 | $357,004 | $68,955 |
| 2020 | 13 | 567 | 594 | $346,465 | $63,834 |
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 163 | 163 | $173,921 | $33,281 | 19.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 125 | 125 | $105,875 | $12,244 | 11.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 93 | 98 | $21,266 | $8,827 | 41.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 40 | 40 | $31,129 | $7,006 | 22.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 87 | 88 | $59,840 | $5,869 | 9.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 63 | 66 | $9,768 | $4,380 | 44.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $9,628 | $2,974 | 30.9% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 16 | 16 | $12,496 | $2,842 | 22.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 27 | 27 | $5,913 | $2,137 | 36.1% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 24 | 24 | $12,432 | $1,785 | 14.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 17 | $3,604 | $1,580 | 43.8% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $9,360 | $1,552 | 16.6% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 12 | 13 | $8,437 | $1,421 | 16.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 132 | 132 | $140,844 | $25,823 | 18.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 91 | 91 | $77,077 | $9,533 | 12.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 97 | 109 | $23,653 | $9,371 | 39.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 54 | 54 | $17,966 | $6,454 | 35.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 86 | 89 | $58,076 | $5,406 | 9.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 23 | 24 | $18,675 | $4,087 | 21.9% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 13 | 13 | $10,153 | $2,337 | 23.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $5,754 | $2,168 | 37.7% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 27 | 28 | $14,504 | $1,964 | 13.5% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 15 | 15 | $11,715 | $1,936 | 16.5% |
| 43262 | Incision of pancreatic outlet using a flexible endoscope | Facility | 2022 | 13 | 13 | $19,617 | $1,367 | 7.0% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2022 | 16 | 17 | $11,033 | $1,283 | 11.6% |
About Dr. Jeffrey Smith, M.D
Dr. Jeffrey Smith, M.D is a Gastroenterology healthcare provider based in Southlake, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1134105083.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Smith, M.D has received a total of $5,235 in payments from pharmaceutical and medical device companies, with $389.05 received in 2024. These payments were reported across 256 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($5,187).
As a Medicare-enrolled provider, Smith has provided services to 2,454 Medicare beneficiaries, totaling 2,530 services with total Medicare billing of $293,538. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Southlake, TX
- Active Since 12/21/2005
- Last Updated 05/16/2013
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1134105083
Products in Payments
- STELARA (Biological) $945.37
- ZEPOSIA (Drug) $354.13
- RINVOQ (Biological) $335.51
- Humira (Biological) $272.10
- OCALIVA (Drug) $245.88
- REMICADE (Biological) $228.66
- SUTAB (Drug) $161.08
- XIFAXAN (Drug) $158.71
- DIFICID (Drug) $144.65
- XIFAXANIBSD (Drug) $137.26
- LINZESS (Drug) $134.29
- Alinia Tablets 500mg 30 count bottle (Drug) $124.91
- XELJANZ (Drug) $119.39
- INJECTAFER (Drug) $113.06
- RELISTOR ORAL (Drug) $103.52
- VIBERZI (Drug) $97.33
- DUPIXENT (Biological) $85.20
- SKYRIZI (Biological) $71.24
- Sucraid (Drug) $62.24
- RENFLEXIS (Drug) $58.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Southlake
Dr. Timothy Ritter, M.d, M.D
Gastroenterology — Payments: $1.1M
Dr. David Levitan, M.d, M.D
Gastroenterology — Payments: $26,370
Dr. James Weber, M.d, M.D
Gastroenterology — Payments: $17,582
Dr. David Spady, M.d, M.D
Gastroenterology — Payments: $12,464
Dr. Stephen Lacey, M.d, M.D
Gastroenterology — Payments: $5,636
Dr. Azaan Ramani, Do, DO
Gastroenterology — Payments: $4,793